Matrix Asset Advisors, Inc. on Abbott Laboratories

Matrix initiated a new partial position in Abbott, a diversified healthcare company spanning medical devices, diagnostics, nutrition, and established pharmaceuticals. The firm likes Abbott’s recurring revenues, strong balance sheet, and 54-year record of dividend increases, while the stock had fallen from a 52-week high of $139 to below $90. At less than 16 times estimated 2026 earnings, roughly a 25% discount to the market and to Abbott’s own valuation history, plus a 2.8% dividend yield at purchase, Matrix sees an attractive combination of quality, valuation, and income.